|
| Product Name: | Dulaglutide | | Synonyms: | Dulaglutide - solution in PBS;Dulaglutide USP/EP/BP;Dulaglutide;Research Grade Dulaglutide(DHE40129) | | CAS: | 923950-08-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | GLP | | Mol File: | Mol File | ![Dulaglutide Structure]() |
| | Dulaglutide Chemical Properties |
| | Dulaglutide Usage And Synthesis |
| Sequence Length | 550 (275, 275)multichain | | Description | Dulaglutide, a GLP-1 receptor agonist that is administered subcutaneously once weekly, has been approved since 2014 for the treatment of adults with type 2 diabetes. | | Indications | Dulaglutide is used together with diet and exercise to help control your blood sugar. This medicine also lowers the risk of death, heart attack, or stroke in patients with diabetes and heart or blood vessel problems. | | Side effects | The most common side effects of Dulaglutide are gastrointestinal issues such as indigestion, decreased appetite, nausea, vomiting, abdominal pain, and diarrhea. Some patients may also experience more serious adverse reactions including acute pancreatitis (characterized by severe and persistent abdominal pain that may spread to the back and accompanied by vomiting), low blood sugar levels (hypoglycemia), and kidney problems that may require hemodialysis. The risk of hypoglycemia is higher when the drug is used in combination with sulfonylureas or insulin. Additionally, there is a potential risk of developing medullary thyroid carcinoma associated with the use of this medication. |
| | Dulaglutide Preparation Products And Raw materials |
|
